Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII
Tramiprosate, like so many others, could have been consigned to the scrap heap of once-promising AD meds that didn’t quite make the grade, never to be studied again. But then in stepped small Framingham, MA-based biotech Alzheon, led by industry veteran Dr. Martin Tolar, who saw potential in